Is Xeris Biopharma Holdings, Inc. (XERS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 28.2% / 30% | 7.4% / 30% | 4.2% / 30% | N/A | ✓ HALAL |
| DJIM | 28.2% / 33% | 7.4% / 33% | 4.2% / 33% | N/A | ✓ HALAL |
| MSCI | 84.0% / 33% | 22.2% / 33% | 12.5% / 33% | N/A | ✗ NOT HALAL |
| S&P | 28.2% / 33% | 7.4% / 33% | 4.2% / 33% | N/A | ✓ HALAL |
| FTSE | 84.0% / 33% | 22.2% / 33% | 12.5% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 85.4% | |
| Operating Margin | 19.5% | |
| Net Margin | 0.2% | |
| Return on Assets (ROA) | 4.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $29M |
| Free Cash Flow | $28M |
| Total Debt | $258M |
| Debt-to-Equity | 1885.4 |
| Current Ratio | 2.2 |
| Total Assets | $384M |
Price & Trading
| Last Close | $5.57 |
| 50-Day MA | $6.50 |
| 200-Day MA | $6.91 |
| Avg Volume | 2.0M |
| Beta | 1.0 |
|
52-Week Range
$3.81
| |
About Xeris Biopharma Holdings, Inc. (XERS)
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Xeris Biopharma Holdings, Inc. (XERS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Xeris Biopharma Holdings, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Xeris Biopharma Holdings, Inc.'s debt ratio?
Xeris Biopharma Holdings, Inc.'s debt ratio is 28.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 84.0%.
What are Xeris Biopharma Holdings, Inc.'s key financial metrics?
Xeris Biopharma Holdings, Inc. has a market capitalization of $931M, trailing P/E ratio of inf, and revenue of $292M. The company maintains a gross margin of 85.4% and a net margin of 0.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.